Lung Cancer Subtyping: A Short Review
Author:
Siddique Farzana1, Shehata Mohamed1ORCID, Ghazal Mohammed2ORCID, Contractor Sohail3, El-Baz Ayman1ORCID
Affiliation:
1. Department of Bioengineering, University of Louisville, Louisville, KY 40292, USA 2. Electrical, Computer, and Biomedical Engineering Department, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates 3. Department of Radiology, University of Louisville, Louisville, KY 40202, USA
Abstract
As of 2022, lung cancer is the most commonly diagnosed cancer worldwide, with the highest mortality rate. There are three main histological types of lung cancer, and it is more important than ever to accurately identify the subtypes since the development of personalized, type-specific targeted therapies that have improved mortality rates. Traditionally, the gold standard for the confirmation of histological subtyping is tissue biopsy and histopathology. This, however, comes with its own challenges, which call for newer sampling techniques and adjunctive tools to assist in and improve upon the existing diagnostic workflow. This review aims to list and describe studies from the last decade (n = 47) that investigate three such potential omics techniques—namely (1) transcriptomics, (2) proteomics, and (3) metabolomics, as well as immunohistochemistry, a tool that has already been adopted as a diagnostic adjunct. The novelty of this review compared to similar comprehensive studies lies with its detailed description of each adjunctive technique exclusively in the context of lung cancer subtyping. Similarities between studies evaluating individual techniques and markers are drawn, and any discrepancies are addressed. The findings of this study indicate that there is promising evidence that supports the successful use of omics methods as adjuncts to the subtyping of lung cancer, thereby directing clinician practice in an economical and less invasive manner.
Reference91 articles.
1. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050;Sharma;Int. J. Clin. Oncol.,2022 2. Epidemiology of lung cancer;Thandra;Współczesna Onkol.,2021 3. Belluomini, L., Calvetti, L., Inno, A., Pasello, G., Roca, E., Vattemi, E., Veccia, A., Menis, J., and Pilotto, S. (2022). SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs. Front. Oncol., 12. 4. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing;Wang;Signal Transduct. Target. Ther.,2022 5. Khodabakhshi, Z., Mostafaei, S., Arabi, H., Oveisi, M., Shiri, I., and Zaidi, H. (2021). Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput. Biol. Med., 136.
|
|